鉅细胞病毒 (CMV) 治疗市场 - 按药物类型（缬更昔洛韦、更昔洛韦、西多福韦、膦甲酸）、应用、给药途径、配销通路- 全球预测，2024 年 - 2032 年

在医疗技术和诊断技术的进步以及人们对早期检测和治疗选择的认识不断提高的推动下，鉅细胞病毒（CMV）治疗市场规模预计在2024 年至2032 年期间将以6.6% 的复合年增长率扩大。

由于免疫系统较弱，器官移植受者和爱滋病毒/爱滋病患者越来越容易感染鉅细胞病毒。随着全球器官移植数量的不断增加以及爱滋病毒/爱滋病病例的不断上升，对有效的鉅细胞病毒治疗方案的需求不断增加。根据 UNOS（器官共享联合网络）的数据，2022 年，进行了超过 42,800 例器官移植，创下了新的年度记录。

医疗保健提供者也认识到在这个脆弱患者群体中预防和管理鉅细胞病毒感染的重要性，以改善临床结果并降低併发症的风险。因此，越来越需要创新疗法和治疗策略，以解决器官移植和爱滋病毒/爱滋病患者中鉅细胞病毒感染带来的独特挑战，从而推动市场成长。

CMV治疗市场根据药物类型、配销通路、给药途径、应用和区域进行分类。

西多福韦药物类型领域的行业规模预计到 2032 年将增长 6.8%，因为该药物抑制病毒 DNA 复製，使其成为对抗 CMV 感染的有效抗病毒药物。广谱活性和良好的安全性使西多福韦成为 CMV 治疗的首选，特别是对于免疫功能低下的患者。此外，延长半衰期、减少给药频率、提高患者依从性和便利性等好处将促进该细分市场的成长。

由于线上药局提供的便利性、可及性和自由裁量权，电子商务平台配销通路领域的鉅细胞病毒治疗市场到 2032 年可能会出现 6.5% 的复合年增长率。电子商务平台通常提供广泛的产品选择、有竞争力的价格和送货上门的服务，进一步增强了对消费者的吸引力。线上购买的成长趋势，加上网路和智慧型手机技术的日益普及，也推动了电子商务在医疗保健领域的扩张。

在医疗保健支出增加、对传染病的认识不断提高以及医疗保健基础设施不断扩大的推动下，亚太地区 CMV 治疗市场预计在 2024 年至 2032 年期间复合年增长率为 7%。在庞大的患者群体和对有效 CMV 治疗方案不断增长的需求的推动下，中国、印度和日本等国家预计将引领市场扩张。此外，旨在改善医疗保健可近性和负担能力的政府措施以及有利的监管政策正在为该地区的行业成长创造有利的环境。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 鉅细胞病毒感染率上升
    • 不断提高的认识和新药物疗法的引入
    • 爱滋病患者传染病病率高
    • CMV 视网膜炎和先天性 CMV 感染患者数量激增
  • 产业陷阱与挑战
    • 与鉅细胞病毒药物相关的不良反应
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 竞争定位矩阵
• 战略仪錶板

第 5 章：市场估计与预测：按药物类型，2018 - 2032

• 主要趋势
• 缬更昔洛韦
• 更昔洛韦
• 西多福韦
• 膦甲酸
• 其他药物种类

第 6 章：市场估计与预测：按应用分类，2018 年 - 2032 年

• 主要趋势
• 干细胞移植
• 器官移植
• 先天性鉅细胞病毒感染
• 其他应用

第 7 章：市场估计与预测：按管理途径，2018 年 - 2032 年

• 主要趋势
• 口服
• 静脉

第 8 章：市场估计与预测：按配销通路，2018 年 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 电子商务

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要动向：按地区
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 10 章：公司简介

• Chimerix, Inc.
• Clinigen Group PLC
• F. Hoffmann-La Roche Ltd
• Fresenius Kabi
• Genentech Inc.
• Gilead Sciences, Inc.
• Merck & Co. Inc
• Mylan N.V
• Pfizer, Inc.
• Takeda Pharmaceuticals
• Teva Pharmaceuticals Inc
• Thermo Fisher Scientific Inc.

Cytomegalovirus (CMV) Treatment Market size is expected to expand at 6.6% CAGR during 2024-2032, driven by advancements in medical technology and diagnostic techniques along with the rising awareness about early detection and treatment options.

Organ transplant recipients and individuals with HIV/AIDS have grown susceptible to CMV infections due to their weakened immune systems. With the increasing number of organ transplantations performed globally and the rising prevalence of HIV/AIDS cases, the demand for effective CMV treatment options is on the rise. As per UNOS (United Network for Organ Sharing), in 2022, over 42,800 organ transplants were performed, setting a new annual record.

Healthcare providers are also recognizing the importance of preventing and managing CMV infections in this vulnerable patient population to improve clinical outcomes and reduce the risk of complications. Consequently, there is a growing need for innovative therapies and treatment strategies tailored to address the unique challenges posed by CMV infection in organ transplant and HIV/AIDS patients, thereby driving the market growth.

The CMV treatment market is classified based on drug type, distribution channel, route of administration, application, and region.

The industry size from the cidofovir drug type segment is expected to record 6.8% growth rate till 2032, as the drug inhibits viral DNA replication, making it an effective antiviral agent against CMV infections. The broad-spectrum activity and favorable safety profile have positioned cidofovir as a preferred choice for CMV treatment, particularly in immunocompromised patients. Furthermore, benefits like extended half-life to offer less frequent dosing for enhancing patient compliance and convenience will add to the segment growth.

Cytomegalovirus treatment market from the E-commerce platform distribution channel segment may witness 6.5% CAGR up to 2032, owing to the convenience, accessibility, and discretion offered by online pharmacies. E-commerce platforms often provide a wide range of product choices, competitive pricing, and doorstep delivery, further enhancing their appeal to consumers. The growing trend of online purchasing, coupled with the increasing penetration of internet and smartphone technologies has also fueled the expansion of e-commerce in the healthcare sector.

Asia Pacific CMV treatment market is poised to depict 7% CAGR during 2024-2032, driven by increasing healthcare expenditure, rising awareness about infectious diseases, and expanding healthcare infrastructure. Countries, such as China, India, and Japan are expected to lead the market expansion, fueled by large patient population and the growing demand for effective CMV treatment options. Furthermore, government initiatives aimed at improving healthcare accessibility and affordability along with favorable regulatory policies are creating conducive environments for industry growth in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameter
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rise in the prevalence of cytomegalovirus infection
    • 3.2.1.2 Growing awareness and introduction of new drug therapies
    • 3.2.1.3 High prevalence of infectious diseases among AIDS patients
    • 3.2.1.4 Upsurge in patient pool of CMV retinitis and congenital CMV infection
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects associated with cytomegalovirus drugs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
  • 3.5.1 Supplier power
  • 3.5.2 Buyer power
  • 3.5.3 Threat of new entrants
  • 3.5.4 Threat of substitutes
  • 3.5.5 Industry rivalry
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Valganciclovir
• 5.3 Ganciclovir
• 5.4 Cidofovir
• 5.5 Foscarnet
• 5.6 Other drug types

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Stem cell transplantation
• 6.3 Organ transplantation
• 6.4 Congenital CMV infection
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Intravenous

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Chimerix, Inc.
• 10.2 Clinigen Group PLC
• 10.3 F. Hoffmann-La Roche Ltd
• 10.4 Fresenius Kabi
• 10.5 Genentech Inc.
• 10.6 Gilead Sciences, Inc.
• 10.7 Merck & Co. Inc
• 10.8 Mylan N.V
• 10.9 Pfizer, Inc.
• 10.10 Takeda Pharmaceuticals
• 10.11 Teva Pharmaceuticals Inc
• 10.12 Thermo Fisher Scientific Inc.